Related Experiment Video
Updated: May 22, 2025

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National
Barbro Kjellström1, Bodil Ivarsson2, Magnus Husberg3
1Department of Clinical Sciences Lund Clinical Physiology and Skåne University Hospital, Lund University Lund Sweden.
Pulmonary arterial hypertension (PAH) significantly increases societal costs, especially post-diagnosis. Idiopathic/hereditary PAH (IPAH/HPAH) incurs the highest costs after diagnosis, driven by healthcare expenses.
Area of Science:
- Cardiology
- Public Health
- Health Economics
Background:
- Pulmonary arterial hypertension (PAH) is a complex condition with various subtypes, including idiopathic/hereditary PAH (IPAH/HPAH), and those associated with connective tissue disease (APAH-CTD) and congenital heart disease (APAH-CHD).
- Societal costs associated with PAH, both before and after diagnosis, are not well-characterized across its different subgroups.
Purpose of the Study:
- To estimate and compare the societal costs in a national PAH cohort, stratified by subgroup, during the 5 years preceding and 5 years following diagnosis.
- To compare these costs against a matched control group to understand the economic burden of PAH.
Main Methods:
- Utilized Swedish national databases to link patient data and estimate societal costs.
- Included incident PAH patients diagnosed between 2008-2019 and matched them 1:5 with a control group based on age, sex, and geography.
- Analyzed pre- and post-diagnosis costs, identifying main cost drivers for both patient and control groups.
Main Results:
- Pre-diagnosis, societal costs were substantially higher in all PAH subgroups compared to controls (2.9-4.3 times).
- Post-diagnosis, costs further increased significantly in PAH groups (1.6-3.1 times) while decreasing in controls.
- Post-diagnosis, healthcare costs (including drugs and inpatient/outpatient care) became the primary driver for PAH patients, accounting for a large proportion of direct costs, whereas hospitalizations dominated control group costs.
Conclusions:
- PAH imposes a significant societal economic burden, with costs escalating dramatically after diagnosis.
- APAH-CHD exhibited the highest relative societal costs pre-diagnosis, while IPAH/HPAH incurred the highest overall societal costs post-diagnosis.
- The findings highlight the substantial economic impact of PAH, emphasizing the need for cost-effective management strategies and support systems.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

